Skip to main content
Katherine Ehrenreich 2021 Headshot

Katherine Ehrenreich, MSc

Project Director

Katherine Ehrenreich is a Project Director for a portfolio of studies aiming to create an evidence base for over-the-counter (OTC) medication abortion. Her work includes implementation and oversight of multiple research studies focused on exploring the feasibility of an OTC model of abortion care and people’s experiences accessing medication abortion. Katherine has a background in qualitative research design and analysis, and has over a decade of experience in social science research and program implementation related to abortion. Her previous experience includes implementation of an abortion and contraception service delivery model internationally. Katherine received her BA in Anthropology from Macalester College and her MSc in Reproductive and Sexual Health Research from the London School of Hygiene and Tropical Medicine.

The latest research

See all
April 13, 2026

Examining the association between prior medical mistreatment and interest in and support for over-the-counter medication abortion among people seeking in-person abortion in the United States

Merz-Herrala AA, Biggs MA, Ehrenreich K, Kaller S, Ralph LJ, Scott KA, Kapp N, Kromenaker T, Perritt J, Kari White, Grossman D. Examining the association between prior medical mistreatment and interest in and support for over-the-counter medication abortion among people seeking in-person abortion in the United States. BMC Health Services Research. April 2026; https://doi.org/10.1186/s12913-026-14505-2.
January 2, 2026

Development of a consumer information leaflet for a prototype over-the-counter mifepristone and misoprostol medication abortion product

Ehrenreich K, Biggs MA, Kaller S, Ralph LJ, Blanchard K, Bustamante CK, Cervantes M, Hauser D, Hernández E, Kapp N, Kromenaker T, Moayedi G, Perritt J, Raymond EG, Kari White, Grossman D. Development of a consumer information leaflet for a prototype over-the-counter mifepristone and misoprostol medication abortion product. Contraception. January 2026; https://doi.org/10.1016/j.contraception.2025.111361.
March 26, 2025

No-Test Screening Protocols May Disproportionately Exclude Structurally Oppressed Communities Who Could Benefit from Accessing Medication Abortion

Biggs MA, Ralph LJ, Ehrenreich K, Kaller S, Blanchard K, Hauser D, Kapp N, Kromenaker T, Moayedi G, Perritt J, Raymond EG, Kari White, Grossman D. No-Test Screening Protocols May Disproportionately Exclude Structurally Oppressed Communities Who Could Benefit from Accessing Medication Abortion. Health Equity. March 2025; https://doi.org/10.1089/heq.2024.0128.
January 9, 2025

Accuracy of survey-based assessment of eligibility for medication abortion compared with clinician assessment

Ralph LJ, Ehrenreich K, Kaller S, Gurazada T, Biggs MA, Blanchard K, Hauser D, Kapp N, Kromenaker T, Moayedi G, Gil JP, Perritt J, Raymond EG, Taylor D, Kari White, Valladares ES, Williams S, Grossman D. Accuracy of survey-based assessment of eligibility for medication abortion compared with clinician assessment. American Journal of Obstetrics & Gynecology. January 2025; https://doi.org/10.1016/j.ajog.2025.01.008.